Introduction: Gait impairment is common in multiple sclerosis (MS), but difficult to evaluate in clinical practice. In this proof-of-concept observational study, we compared walking ability recorded by Google Maps Timeline to conventional clinical measures in people with MS. Methods: We used open-access Google Maps Timeline to record the total number of days with walking activity, walking distance, walking time, and walking speed. Each Google Maps Timeline variable was included in a different stepwise linear regression model including all conventional clinical variables. Results: We included nine people with MS (age 43.1 ± 6.6 years; females 55.6%; disease duration 12.7 ± 3.1 years; median Expanded Disability Status Scale 3.0 (range 1.0–5.5)). Higher percentage of days with recorded walking was associated with lower Fatigue Severity Scale ( p = 0.01), and higher MS Walking Scale ( p = 0.04). Longer average daily walking distance was associated with shorter Timed-25 Foot Walking Test ( p = 0.02), lower Expanded Disability Status Scale ( p = 0.01), and higher Euro-Quality of Life ( p = 0.04). Longer average daily walking time was associated with shorter Timed-25 Foot Walking Test ( p = 0.03). Higher walking speed was associated with lower Fatigue Severity Scale ( p = 0.04). Conclusion: Google Maps Timeline parameters provide actual estimates of daily walking activities in MS.
Introduction: Although panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) have been described as complications following immunosuppressive treatments, there are no reported cases of concomitant SPTCL/HSP and multiple sclerosis (MS). Materials and Methods: We describe the case of a patient affected by an aggressive phenotype of relapsing remitting MS, characterized by consecutive severe relapses with no complete remission. He developed panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) after receiving multiple immunosuppressive treatments in sequence. Despite the aggressive nature of these complications, the patient responded well to a combination of Gemcitabine and Cisplatin. Discussion and Conclusions: With this case, we suggest that physicians always consider blood diseases as possible MS therapy complications, especially in the sequencing setting, and also consider uncommon treatments in those with autoimmune predispositions.